Fundraising Fox
🦊/Companies
Sign in

Cumulus Oncology

5 known investors

Find your way into Cumulus Oncology

99 people in our graph share verified history with the Cumulus Oncology team — schools, employers, funds. One of them is your warm intro.

Alain Huriezunlockedknows Clare Wareing · together at Quintiles (overlapped)
knows the team · via Chiltern
×2knows the team · via The University of Edinburgh
×8knows the team · via Quintiles

Cumulus Oncology is a drug development company specializing in oncology therapeutics, leveraging experienced leadership with track records in new drug applications and successful M&A transactions. The company builds a risk-adjusted portfolio in the life sciences and pharmaceutical sector.

BiotechHealthtechLongevityMedical Devices

Founders & leadership

C
CatherineCEO
CWClare Wareing
Clare WareinginCEOClare Wareing founded and leads Cumulus Oncology, a drug development company building a portfolio of oncology therapeutics. She brings over 30 years of experience in oncology drug development, including work on programs that advanced to successful drug approvals, and a track record of founding and scaling clinical development companies.
B
Brian

Investors · 5

Alba EquityAberdeen
Apollo Informal InvestmentEdinburgh
Eos AdvisorySt Andrews
Scottish National Investment BankEdinburgh · $1.3M
Scottish EnterprisereportedGlasgow

Funding

SEC filings, press & company announcements

$5.6M disclosed across 1 of 3 rounds · 2022–2024

Source: company announcements and press reports — follow each round's link for the claim.

Companies House · registry record

View on Companies House ↗
Registered name
CUMULUS ONCOLOGY LIMITED
Company number
SC581311
Status
Active
Company type
Private limited company
Incorporated
13 Nov 2017
Registered office
61 Dublin Street, Edinburgh, Midlothian, EH3 6NL
Nature of business (SIC)
72110 — Research and experimental development on biotechnology72190 — Other research and experimental development on natural sciences and engineering
Accounts
last made up to 31 Dec 2024 · next due 30 Sept 2026
Confirmation statement
last made up to 12 Nov 2025 · next due 26 Nov 2026

Current officers · 7

  • James Alexander Fair — secretary, appointed 8 Sept 2023
  • Manuel Alves Aivado — director, appointed 7 Jul 2025
  • Brian Michael Gallagher Jr — director, appointed 9 Dec 2024
  • Catherine Elizabeth Lewis La Torre — director, appointed 1 Jun 2024
  • Andrew Paul Mcneill — director, appointed 9 Jun 2020
  • Keith Murdoch — director, appointed 9 Jun 2020
  • Clare Jane Wareing — director, appointed 13 Nov 2017

Source: Companies House public register · retrieved 6 Sept 2026. Contains public sector information licensed under the Open Government Licence v3.0.

In the news

Cumulus Oncology secures £9 million funding - Business Insiderinsider.co.uk · Jan 2024Cumulus Oncology raises £9m in seed financingglobenewswire.com · Jan 2024Cumulus Oncology raises $5.6 million funding led by Eos Advisory » World Business Outlookworldbusinessoutlook.com · Feb 2022Cumulus Oncology Secures £4.1m ($5.6m) Investment Led by Eos Advisorybusinesswire.com · Feb 2022Edinburgh cancer discovery accelerator Cumulus gets £4.1 million funding injectionscotsman.com · Feb 2022Cumulus Oncology | Scottish Financial Newsscottishfinancialnews.com

Frequently asked questions

What does Cumulus Oncology do?
Cumulus Oncology is a drug development company specializing in oncology therapeutics, leveraging experienced leadership with track records in new drug applications and successful M&A transactions. The company builds a risk-adjusted portfolio in the life sciences and pharmaceutical sector.
Who founded Cumulus Oncology?
Cumulus Oncology was founded by Catherine.
Who are Cumulus Oncology's investors?
Cumulus Oncology's investors include Alba Equity, Apollo Informal Investment, Eos Advisory, Scottish National Investment Bank, Scottish Enterprise.
How much funding has Cumulus Oncology raised?
Cumulus Oncology has disclosed $5.6M raised across 1 of its 3 known rounds.